

**Table S2. Potency and efficacy of follow up compounds**

#	ID	Series <sup>1</sup>	qHTS		Retest					Confirmation			
			$\mu\text{M}$ IC <sub>50</sub>	% Eff <sup>2</sup>	$\mu\text{M}$ IC <sub>50</sub> R	% Eff R	$\mu\text{M}$ IC <sub>50</sub> G	% Eff G	$\mu\text{M}$ IC <sub>50</sub> Tox <sup>3</sup>	$\mu\text{M}$ IC <sub>50</sub> R	% Eff R	$\mu\text{M}$ IC <sub>50</sub> G	% Eff G
1	MLS000517530-01	1	14	-50	10	-80	8	-56	-	5	-75	4	-72
2	MLS000389544-01	1	36	-69	22	-99	10	-81	-	5	-96	5	-92
3	MLS000517219-01	1	-	-	4*	-43	-	-	-	-	-	-	-
4	MLS000565365-01	2	22	-33	45	-53	25	-83	-	-	-	-	-
5	MLS000043700-01	2	25	-52	16	-95	9*	-89	-	-	-	-	-
6	MLS000043701-01	2	-	-	45	-90	28*	-74	-	-	-	-	-
7	NCGC00183215-01	2	-	-	-	-	-	-	-	-	-	34*	-124
8	MLS000678325-01	3	18	-31	40	-78	†	†	-	32*	-161	-	-
9	MLS000566850-01	3	-	-	-	-	-	-	-	-	-	-	-
10	MLS000374995-01	4	40	-58	†	†	-	-	-	-	-	-	-
11	MLS000051497-01	5	36	-61	†	†	-	-	-	-	-	-	-
12	MLS001003683-01	6	32	-37	92*	-69	79*	-66	-	-	-	-	-
13	MLS000592203-01	7	36	-64	-	-	-	-	-	-	-	-	-
14	NCGC00123501-01	8	0.8*	-35	-	-	-	-	-	-	-	-	-
15	MLS000566126-01	9	1	-47	-	-	†	†	-	-	-	-	-
16	MLS000097492-01	9	32	-47	92*	-81	40	-60	-	-	-	-	-
17	MLS000391116-01	9	-	-	-	-	-	-	-	-	-	-	-
18	MLS000554429-01	10	32	-56	†	†	79	-56	-	-	-	-	-
19	MLS000554947-01	10	45	-35	56	-82	50*	-44	-	-	-	-	-
20	MLS000526361-01	10	25*	-60	†	†	†	†	-	-	-	-	-
21	MLS000042510-01	11	36	-62	92	-41	-	-	-	-	-	-	-
22	MLS000718932-01	12	2	-38	1	-50	†	†	3	-	-	-	-
23	MLS000768805-01	12	-	-	-	-	-	-	-	-	-	-	-
24	MLS000858701-01	13	4	-39	32	-52	92	-47	-	-	-	-	-
25	MLS000588660-01	14	4	-43	†	†	†	†	-	-	-	-	-
26	MLS000557855-01	14	14	-44	89	-81	36*	-46	-	-	-	-	-
27	MLS000595296-01	14	-	-	-	-	-	-	-	-	-	-	-
28	MLS000030506-01	15	9	-33	†	†	-	-	-	-	-	-	-
29	MLS000763081-01	16	11	-41	92	-72	32	-46	-	-	-	-	-
30	MLS000339510-01	17	36	-100	†	†	-	-	-	-	-	-	-
31	MLS000587883-01	18	0.01	-32	†	†	-	-	-	-	-	-	-
32	MLS000736037-01	19	32	-41	92	-78	†	†	-	-	-	-	-
33	MLS000086665-01	20	0.1	-33	†	†	-	-	-	-	-	-	-
34	NCGC00126685-01	21	6*	-34	-	-	-	-	-	-	-	-	-
35	NCGC00098234-01	22	4*	-11	†	†	-	-	-	-	-	-	-
36	MLS000737424-01	23	11	-46	92	-79	32*	-40	25	-	-	-	-
37	NCGC00094767-01	23	-	-	†	†	-	-	31	-	-	-	-
38	MLS000073645-01	23	28*	-93	89	-63	20	-49	-	-	-	-	-
39	NCGC00115663-01	24	32*	-54	-	-	-	-	-	-	-	-	-
40	MLS000775306-01	25	14	-35	-	-	†	†	-	-	-	-	-
41	MLS000775307-01	25	-	-	†	†	-	-	-	-	-	-	-
42	MLS000394821-01	25	40*	-77	-	-	-	-	-	-	-	-	-
43	MLS000580791-01	26	25	-40	†	†	79	-45	-	-	-	-	-
44	MLS000532367-01	27	28	-33	45	-86	28	-44	-	-	-	-	-
45	NCGC00016896-01	28	17	-32	92	-62	†	†	-	-	-	-	-

#	ID	Series <sup>1</sup>	qHTS		Retest					Confirmation				
			$\mu\text{M}$ IC <sub>50</sub>	% Eff <sup>2</sup>	$\mu\text{M}$ IC <sub>50</sub> R	% Eff R	$\mu\text{M}$ IC <sub>50</sub> G	% Eff G	$\mu\text{M}$ IC <sub>50</sub> Tox <sup>3</sup>	$\mu\text{M}$ IC <sub>50</sub> R	% Eff R	$\mu\text{M}$ IC <sub>50</sub> G	% Eff G	
46	MLS000069829-01	28	-	-										
47	MLS000333070-01	29	40	-54	†	†	-	-	-					
48	MLS000588145-01	30	18*	-126	†	†	-	-	-					
49	MLS000040484-01	31	7	-40	-	-	-	-	-					
50	MLS000332102-01	31	-	-	-	-	-	-	-					
51	MLS001010770-01	32	36	-53	79	-121	-	-	-					
52	MLS000591766-01	33	40	-51	40	-71	13	-41	-					
53	MLS000549845-01	34	32	-77	-	-	-	-	-					
54	MLS000051772-01	35	32	-54	50	-99	20	-71	-					
55	NCGC00168048-01	36	14	-49	92*	-231	40*	-229	8					
56	MLS000594813-01	37	18	-45	†	†	45	-51	-					
57	MLS000038680-01	37	25	-65	†	†	-	-	-					
58	MLS000038679-01	37	36	-76	†	†	56	-43	-					
59	MLS000710923-01	38	6	-76	7	-124	4	-79	-					
60	MLS000069532-01	38	16	-40	8	-113	3	-92	-					
61	MLS000774398-01	39	32	-91	9	-83	6	-85	-					
62	MLS000850935-01	39	32	-74	50	-103	50	-88	-					
63	MLS001029609-01	40	11	-32	50	-103	32	-57	-					
64	MLS000391126-01	40	36	-56	45	-101	10	-44	-					
65	MLS000334232-01	40	45	-53	40	-96	40	-79	-					
66	MLS000071484-01	41	36	-59	32*	-83	8*	-42	-					
67	MLS000541038-01	41	71	-67	40*	-115	32*	-71	-					
68	MLS000026910-01	41	36*	-69	40*	-91	32	-57	-					
69	MLS000555090-01	41	40*	-56	36*	-122	13	-62	-					
70	MLS000106099-01	41	50*	-71	25*	-72	20*	-46	-					
71	NCGC00100433-01	42a	14	-45	92	-97	79	-65	-					
72	NCGC00100429-01	42a	56	-46	50	-81	20	-60	-					
73	MLS000531260-01	42a	71	-54	92	-96	36	-58	-					
74	MLS000531050-01	42a	79	-49	†	†	†	†	-					
75	NCGC00100427-01	42a	-	-	92	-51	79	-52	-					
76	MLS000540052-01	42b	4	-38	79	-43	79	-54	-					
77	MLS000592130-01	42b	-	-	92	-60	32	-41	-					
78	MLS000123832-01	42c	14	-66	56	-68	36	-41	-					
79	MLS000715671-01	42c	22	-34	16	-58	†	†	-	-	-	-	-	-
80	MLS000715977-01	42c	-	-	92	-73	32	-49	-					
81	MLS000833701-01	42d	36	-42	-	-	-	-	-					
82	MLS000064439-01	42e	25	-64	-	-	-	-	-					
83	MLS000389027-01	42f	14	-39	-	-	-	-	-					
84	MLS000736512-01	S1	22	-44	11	-63	4	-45	-	37*	-169	4	-29	
85	MLS000035420-01	S2	32	-81	†	†	56	-57	-					
86	MLS000037143-01	S3	50	-58	92	-135	89*	-64	18					
87	MLS000107641-01	S4	40	-45	45*	-124	14*	-192	-					
88	MLS000334609-01	S5	36*	-60	†	†	-	-	-					
89	MLS000530477-01	S6	16	-51	†	†	†	†	-					
90	MLS000532711-01	S7	40	-48	†	†	-	-	-					
91	MLS000533245-01	S8	28	-71	92	-63	-	-	-					

#	ID	Series <sup>1</sup>	qHTS		Retest					Confirmation			
			$\mu\text{M}$ IC <sub>50</sub>	% Eff <sup>2</sup>	$\mu\text{M}$ IC <sub>50</sub> R	% Eff R	$\mu\text{M}$ IC <sub>50</sub> G	% Eff G	$\mu\text{M}$ IC <sub>50</sub> Tox <sup>3</sup>	$\mu\text{M}$ IC <sub>50</sub> R	% Eff R	$\mu\text{M}$ IC <sub>50</sub> G	% Eff G
92	MLS000539207-01	S9	45	-45	†	†	-	-	-				
93	MLS000572533-01	S10	50	-43	89	-55	-	-	-				
94	MLS000736244-01	S11	45	-59	†	†	79	-79	-				
95	NCGC00024515-01	S12	32	-42	†	†	-	-	<0				
96	NCGC00115021-01	S13	10	-64	†	†	-	-	-				
97	NCGC00115357-01	S14	3*	-43	†	†	-	-	-				
98	MLS000117623-01	S15	50	-44	45*	-169	40*	-128	-				
99	NCGC00168026-01	S16	13	-31	25	-73	20	-48	22	39	-51	65	-48
100	NCGC00164166-01	S17	112	-50	92	-95	63	-73	-				
101	NCGC00091101-02	S18	28	-23	40	-124	16	-75	35				
102	MLS000039785-01	S19	79	-66	-	-	-	-	-				
103	MLS000419418-01	S20	18	-38	-	-	40	-40	-				
104	MLS000529158-01	S21	45	-45	-	-	-	-	-				
105	MLS000529931-01	S22	50*	-89	-	-	-	-	-				
106	MLS000530963-01	S23	40	-49	-	-	-	-	-				

Notes. <sup>1</sup>Numbers beginning with S indicate singletons. <sup>2</sup>Percent efficacy is the maximum response as determined by the curve fit of the titration-response data. <sup>3</sup>Activity in cell viability assay. \*TF active indicating possible compound interference. R, FP assay using Texas red fluoroprobe; G, FP assay using fluorescein fluoroprobe; †, active with efficacy <40%; -, Inactive.